United Therapeutics Co. (NASDAQ:UTHR) Stock Position Increased by Cardinal Capital Management

Cardinal Capital Management lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 20.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,955 shares of the biotechnology company’s stock after purchasing an additional 1,675 shares during the period. Cardinal Capital Management’s holdings in United Therapeutics were worth $2,287,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $32,000. GAMMA Investing LLC acquired a new position in United Therapeutics during the fourth quarter valued at $43,000. Janiczek Wealth Management LLC raised its position in United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the period. Blue Trust Inc. raised its position in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. Finally, Quadrant Capital Group LLC raised its position in United Therapeutics by 31.2% during the fourth quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 138 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,166.50. The disclosure for this sale can be found here. Insiders sold a total of 122,744 shares of company stock valued at $31,286,630 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $2.02 during trading hours on Thursday, hitting $316.93. 458,265 shares of the company’s stock were exchanged, compared to its average volume of 498,540. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $321.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock has a market capitalization of $14.06 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 4.77 and a beta of 0.49. The company’s 50-day moving average price is $271.56 and its 200-day moving average price is $243.07.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.86 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on UTHR. HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Wells Fargo & Company upped their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Finally, Oppenheimer boosted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $312.22.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.